SCHEMBL1340545

SCHEMBL1340545

CC1=CCCC(CCOCc2ccccc2)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.39
AGTR2 P50052 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
PDE4D Q08499 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
LTA4H P09960 1/20 0.35
CTSL P07711 1/20 0.35
CTSB P07858 1/20 0.35
CTSK P43235 1/20 0.35
CYP2C19 P33261 1/20 0.34
CHRM3 P20309 1/20 0.34
DRD2 P14416 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
HTR2B P41595 1/20 0.33
SIGMAR1 Q99720 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12266802 0.83 TSHR (0.37) TSHRAGTR2TDP1L3MBTL1LMNA
SCHEMBL1198513 0.81 PDE4D (0.39) TSHRAGTR2LMNAHTTPDE4D
SCHEMBL12266810 0.80 AGTR2 (0.42) AGTR2L3MBTL1HTTPDE4DCYP2C19
SCHEMBL1198756 0.78 AGTR2 (0.40) AGTR2TDP1L3MBTL1LMNAHTT
SCHEMBL12982403 0.78 TSHR (0.54) TSHRAGTR2TDP1L3MBTL1LMNA
SCHEMBL25447679 0.77 TSHR (0.45) TSHRAGTR2TDP1L3MBTL1LMNA
SCHEMBL1198116 0.76 AGTR2 (0.32) TSHRAGTR2TDP1L3MBTL1LMNA
SCHEMBL6647671 0.75 TSHR (0.50) TSHRAGTR2TDP1L3MBTL1LMNA
SCHEMBL18950906 0.75 TSHR (0.50) TSHRAGTR2LMNAHTTPDE4D
SCHEMBL1339794 0.74 LMNA (0.37) TSHRAGTR2TDP1L3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8071635-B2 Minimal cardivascular and/or sedatory activity; treating pain and allodynia; selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors; ALLERGAN, INC. (US) 2011-12-06 US disclosed
US-8063086-B2 Modulators of alpha2B and/or alpha2C adrenergic receptors; alleviate chronic pain, allodynia, muscle spasticity, diarrhea, neuropathic pain; 4-(substituted cycloalkylmethyl)imidazole-2-thione and 4-(substituted cycloalkenylmethyl)imidazole-2-thione compounds ALLERGAN, INC. (US) 2011-11-22 US disclosed
US-8063087-B2 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazole-2-ones and, 4-(substituted cycloalkylmethyl) imidazole-2-ones and related compounds ALLERGAN, INC. (US) 2011-11-22 US disclosed
US-7960423-B2 selective to alpha2B and/or alpha2C adrenergic receptors, minimal cardivascular and/or sedatory activity; pain ALLERGAN, INC (US) 2011-06-14 US disclosed
US-7569584-B2 4-(2-methyl-5,6,7,8-tetrahydro-quinolin-7-ylmethyl)-1,3-dihydro-imidazole-2-thione as specific alpha2b agonist and methods of using the same ALLERGAN, INC. (US) 2009-08-04 US disclosed
US-20080319013-A1 4-(SUBSTITUTED CYCLOALKYLMETHYL) IMIDAZOLE-2-THIONES, 4-(SUBSTITUTED CYCLOALKENYLMETHYL) IMIDAZOLE-2-THIONES, 4-(SUBSTITUTED CYCLOALKYLMETHYL) IMIDAZOLE-2-ONES AND, 4-(SUBSTITUTED CYCLOALKYLMETHYL) IMIDAZOLE-2-ONES AND RELATED COMPOUNDS ALLERGAN, INC. (US) 2008-12-25 US disclosed
US-20080221186-A1 4-(substituted cycloalkylmethyl) Imidazole-2-Thiones, 4-(substituted cycloalkenylmethyl) Imidazole-2-Thiones, 4-(substituted cycloalkylmethyl) Imidazol-2-Ones and 4-(substituted cycloalkenylmethyl) Imidazole-2-Ones and related compounds CHOW KEN 2008-09-11 US disclosed
US-7419994-B2 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2- thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cyloalkenylmethyl) imidazol-2-ones and related compounds ALLERGAN, INC. (US) 2008-09-02 US disclosed
US-20080097103-A1 IMIDAZOLE-2-THIONES CHOW KEN 2008-04-24 US disclosed
US-20080091028-A1 IMIDAZOLE-2-THIONES ALLERGAN, INC. (US) 2008-04-17 US disclosed
US-7276522-B2 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds ALLERGAN, INC. (US) 2007-10-02 US disclosed
US-20070072926-A1 Dextrorotatory and levo-rotatory enantiomers; specific to alpha2B adrenergic receptors; chronic pain, allodynia, muscle spasticity, diarrhea, neuropathic pain and other diseases ALLERGAN, INC. 2007-03-29 US disclosed
US-7091232-B2 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds ALLERGAN, INC. (US) 2006-08-15 US disclosed
US-20060149072-A1 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2- thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cyloalkenylmethyl) imidazol-2-ones and related compounds CHOW KEN 2006-07-06 US disclosed
WO-2006036404-A1 4-(SUBSTITUTED CYCLOALKYLMETHYL) IMIDAZOLE-2-THONES, 4-(SUBSTITUTED CYCLOALKENYLMETHYL) IMIDAZOLE-2-THIONES, 4-(SUBSTITUTED CYLOALKYLMETHYL) IMIDAZOL-2-ONES, 4-(SUBSTITUTED CYCLOALKENYLMETHYL) IMIDAZOL-2-ONES AND RELATED COMPOUNDS ALLERGAN, INC. (US) 2006-04-06 WO disclosed
US-20050267186-A1 4-(Substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4- (substituted cycloalkylmethyl) imidazol-2-ones and 4- (substituted cycloalkenylmethyl) imidazol-2-ones and related compounds CHOW KEN 2005-12-01 US disclosed
US-20050075366-A1 4-(2-Methyl-5,6,7,8-tetrahydro-quinolin-7-ylmethyl)-1,3-dihydro-imidazole-2-thione as specific alpha2B agonist and methods of using the same ALLERGAN, INC. 2005-04-07 US disclosed
EP-1507767-A1 4-SUBSTITUTED IMIDAZOLE-2-THIONES AND IMIDAZOL-2-ONES AS AGONISTS OF THE ALPHA-2B AND ALPHA-2C ADRENERGIC RECEPTORS Allergan, Inc. (US) 2005-02-23 EP disclosed
US-20040220402-A1 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds ALLERGAN, INC. 2004-11-04 US disclosed
WO-2003099795-A1 4-SUBSTITUTED IMIDAZOLE-2-THIONES AND IMIDAZOL-2-ONES AS AGONISTS OF THE ALPHA-2B AND ALPHA-2C ADRENERGIC RECEPTORS ALLERGAN, INC. (US) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220402-A1 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds ADRB2, ADRA2C, ADRB1 TSHR 246/4885AGTR2 59/4885TDP1 1395/4885
US-20080097103-A1 IMIDAZOLE-2-THIONES ADRB2, ADRA2C, ADRA2B TSHR 269/4885AGTR2 83/4885TDP1 1299/4885
US-20050267186-A1 4-(Substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4- (substituted cycloalkylmethyl) imidazol-2-ones and 4- (substituted cycloalkenylmethyl) imidazol-2-ones and related compounds ADRB2, ADRA2C, ADRA2A TSHR 343/4885AGTR2 43/4885TDP1 1875/4885
US-20080091028-A1 IMIDAZOLE-2-THIONES ADRB2, ADRA2C, ADRA2B TSHR 341/4885AGTR2 69/4885TDP1 1339/4885
US-20080319013-A1 4-(SUBSTITUTED CYCLOALKYLMETHYL) IMIDAZOLE-2-THIONES, 4-(SUBSTITUTED CYCLOALKENYLMETHYL) IMIDAZOLE-2-THIONES, 4-(SUBSTITUTED CYCLOALKYLMETHYL) IMIDAZOLE-2-ONES AND, 4-(SUBSTITUTED CYCLOALKYLMETHYL) IMIDAZOLE-2-ONES AND RELATED COMPOUNDS ADRB2, ADRA2C, ADRA2B TSHR 300/4885AGTR2 39/4885TDP1 1501/4885
US-20080221186-A1 4-(substituted cycloalkylmethyl) Imidazole-2-Thiones, 4-(substituted cycloalkenylmethyl) Imidazole-2-Thiones, 4-(substituted cycloalkylmethyl) Imidazol-2-Ones and 4-(substituted cycloalkenylmethyl) Imidazole-2-Ones and related compounds ADRB2, ADRA2C, ADRA2B TSHR 233/4885AGTR2 45/4885TDP1 1625/4885
US-20070072926-A1 Dextrorotatory and levo-rotatory enantiomers; specific to alpha2B adrenergic receptors; chronic pain, allodynia, muscle spasticity, diarrhea, neuropathic pain and other diseases ADRA2A, ADRA2B, ADRB2 TSHR 473/4885AGTR2 62/4885TDP1 1614/4885
US-20050075366-A1 4-(2-Methyl-5,6,7,8-tetrahydro-quinolin-7-ylmethyl)-1,3-dihydro-imidazole-2-thione as specific alpha2B agonist and methods of using the same ADRB2, ADRA2C, ADRA2B TSHR 375/4885AGTR2 29/4885TDP1 2294/4885
US-20060149072-A1 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2- thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cyloalkenylmethyl) imidazol-2-ones and related compounds ADRB2, ADRA2C, ADRA2B TSHR 272/4885AGTR2 53/4885TDP1 1901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.